Allogenic human umbilical derived mesenchymal stem cells(Aspire Health Science)

N/A

Report date: 2024/11/24 20:00:04

Base Information

Drug NameAllogenic human umbilical derived mesenchymal stem cells(Aspire Health Science)

Drug Alias NameACT-20

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAspire Health Science

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAspire Health Science

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A